New Stock News | It is reported that Zhongji Innolight (300308.SZ) has started a pre-IPO roadshow for its Hong Kong listing, with plans to raise up to $8 billion.
If the listing is successful, Zhongji Xuchuang is expected to become the largest IPO in the Hong Kong market since Alibaba in 2019.
Optical module leader Zhongji Innolight (300308.SZ) has successfully completed the listing hearing on the main board of the Hong Kong Stock Exchange on July 17th. According to media reports, the company began its listing roadshow on July 20th to evaluate investor interest, with a potential fundraising of up to $8 billion (approximately HK$62.4 billion). The bookbuilding process is expected to commence as early as this week. If the listing is successful, Zhongji Innolight could become the largest IPO in the Hong Kong market since Alibaba's listing in 2019.
Zhongji Innolight's Hong Kong IPO has been approved by the China Securities Regulatory Commission. The company plans to issue a maximum of 94,004,350 overseas listed ordinary shares and list them on the Hong Kong Stock Exchange, with Goldman Sachs, CICC, Morgan Stanley, and GF SECS as its joint sponsors.
According to the prospectus, Zhongji Innolight is a global leader in optical interconnect solutions. The company's optical interconnect solutions use fiber optics to transmit data, providing high-speed, energy-efficient, and low-latency connections between servers, switches, and other network devices in increasingly complex and data-intensive cloud and AI infrastructure. The company's main product is optical modules, which transmit data by converting electrical signals into optical signals.
According to Zhishizixun, the company has been the world's largest revenue-scale optical interconnect solution provider for five consecutive years since 2021, with a projected 21.2% share of the overall optical interconnect solutions market in 2025. It has also further consolidated its leading position in the high-speed data communication optical interconnect solutions market, with a 28.1% market share in the same year.
Related Articles

JUNSHI BIO (01877): The supplemental application for the use of Tropil Single Top Antibody in combination with chemotherapy for adjuvant therapy in patients with resectable stage II-III non-small cell lung cancer has been accepted.

Market volatility + Tesla's public listing attracts retail investors! Trading frenzy boosts Charles Schwab Corp (SCHW.US) Q2 earnings beyond expectations.

Shenzhen Energy Group (000027.SZ) intends to invest in the construction of the 50MW solar power project in Ghana, Natamale.
JUNSHI BIO (01877): The supplemental application for the use of Tropil Single Top Antibody in combination with chemotherapy for adjuvant therapy in patients with resectable stage II-III non-small cell lung cancer has been accepted.

Market volatility + Tesla's public listing attracts retail investors! Trading frenzy boosts Charles Schwab Corp (SCHW.US) Q2 earnings beyond expectations.

Shenzhen Energy Group (000027.SZ) intends to invest in the construction of the 50MW solar power project in Ghana, Natamale.

RECOMMEND





